uBriGene’s LVV Turbo™ lentivirus production platform integrates three cutting-edge technologies to deliver higher-yield, high-potency lentivirus at lower cost.
Download Brochure
Compare RNA-LNP vs. Sendai virus for PBMC-to-iPSC reprogramming. Learn how RNA-LNP enables faster workflows, lower costs, and high-quality iPSC generation.
Discover how uVivo™ LVV is advancing the next generation of in vivo CAR-T therapy with targeted T-cell delivery, rapid in vivo CAR-T generation, and scalable off-the-shelf potential.
Explore FDA-registered manufacturing, premium MSC, exosome, and EV products, plus scalable, compliant solutions backed by 10+ years of cGMP expertise.
Learn how cutting-edge technologies to alleviate lentiviral supply constraints, reduce manufacturing costs, and support seamless scale-up from early development through commercial readiness.
Delivering high-quality TIL manufacturing globally, uBriGene Biosciences combines automation, scalability, and precision with over 10 successful GMP batches.
Learn how uBriGene can deliver high efficiency total solution designed to accelerate the development of iPSC-derived cell therapies.
Unlock safer regenerative therapies with uBriGene’s Genome-Safe iPSC reprogramming built for clinical success.
Redefining RNA Therapeutics: GMP RNA-LNP Manufacturing You Can Trust
Explore how uBriGene's cutting-edge solutions can fast-track iPSC-based therapeutic development, enabling the next generation of disease models and cell therapies.
Explore the fundamentals of RNA drug development and the critical role of in vitro transcription (IVT) in manufacturing workflows.
